Cargando…
IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRPα interaction and FcɣR engagement by simultaneously binding to CD47 and CD20 of B cells
Autores principales: | Yu, Jifeng, Li, Song, Chen, Dianze, Liu, Dandan, Guo, Huiqin, Yang, Chunmei, Zhang, Wei, Zhang, Li, Zhao, Gui, Tu, Xiaoping, Peng, Liang, Liu, Sijin, Bai, Xing, Song, Yongping, Jiang, Zhongxing, Zhang, Ruliang, Tian, Wenzhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991911/ https://www.ncbi.nlm.nih.gov/pubmed/36575242 http://dx.doi.org/10.1038/s41375-022-01805-9 |
Ejemplares similares
-
Cancer Therapy Targeting CD47/SIRPα
por: Dizman, Nazli, et al.
Publicado: (2021) -
Crystal Structure of Human CD47 in Complex with Engineered SIRPα.D1(N80A)
por: Yu, Jifeng, et al.
Publicado: (2022) -
SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the “don’t eat me” signal and activating the “eat me” signal
por: Yu, Jifeng, et al.
Publicado: (2022) -
The SIRPα–CD47 immune checkpoint in NK cells
por: Deuse, Tobias, et al.
Publicado: (2021) -
CD47–SIRPα-targeted therapeutics: status and prospects
por: Maute, R., et al.
Publicado: (2022)